Ascenta Capital’s Post

What doesn't work must to be replaced with what works. "Concluding Thoughts: We found little evidence the Inflation Reduction Act has resulted in a meaningful decrease in the level of VC investment in new drug development. Other data reinforce this perspective: Late-stage private company and public equity valuations, IPOs, follow-on offerings, and mergers and acquisitions in biopharma largely held steady in the 18 months since passage of the IRA and have had a positive start in 2024. " -https://lnkd.in/eDh29DDi #pharma #IRA #InflationReductionAct #vcfunding #IPO #funding

Since 1781, innovation and strategic mergers and acquisitions fueled Takeda Pharmaceutical’s growth.💡 🤝 📈 As they grew, so did the complexity of their Identity management. 🖥️ ⛔ 🔒 This burdened patients, partners, and caregivers with convoluted, siloed experiences. 🩺 🚨 😵💫 Today, with Okta-powered Takeda ID: 🤩 70,000 employees and contractors access crucial business applications 🏥 3.6 million providers, patients, and donors access healthcare services and resources https://bit.ly/3tizrh4

💸 H1 2024 Pharma & Biotech Strategic Acquisitions and Venture Financing. What are the trends? The first half of 2024 has been marked by high-value M&A deals and robust venture financing. Here are some highlights: Top M&A Deals: The largest acquisition was a $16.5 billion in oncology at the discovery stage. Nephrology and gastroenterology also saw significant investments, with deals reaching nearly $5 billion and $4.3 billion respectively. Venture Financing: ARCH Venture Partners dominated the venture financing landscape, leading with a $1 billion deal in April. Other notable investor include Foresite Capital, leading 2 of the biggest H1 2024 deals. With oncology leading both M&A and venture investments, it's clear that this therapeutic area continues to be a priority. Needs help to analyze potential M&A ? Contact us at: contact@genchrome.com #merger #acquisition #capitalraising #biotech #pharma

Slow activity in Q2 – both M&A and IPOs – for the Biotech sector… confirming 1/ that the flurry of M&A dealmaking end of 2023 has cooled off in H1 2024 and 2/that the IPO market is still slow to recover (even if there have been tentative signs of improvement in recent months)

To build competitive and sustainable portfolios, biopharma companies need to continuously assess their program and asset management strategies, namely: building proprietary platforms/technologies, other company/asset acquisitions, and strategic partnerships. Each strategy has different capital requirements, operational structures, and degree of risk. So, how should companies juggle these 3 balls? The current article provides valuable insights into the evaluation of these strategies with representative recent examples from the industry. #biopharma #M&A #Innovation #Partnerships #assetmanagement

💲Top M&A Deals: The largest acquisition was a $16.5 billion in oncology at the discovery stage. Nephrology and gastroenterology also saw significant investments, with deals reaching nearly $5 billion and $4.3 billion respectively. Venture Financing: ARCH Venture Partners dominated the venture financing landscape, leading with a $1 billion deal in April. Other notable investor include Foresite Capital, leading 2 of the biggest H1 2024 deals. With oncology leading both M&A and venture investments, it's clear that this therapeutic area continues to be a priority. Needs help to analyze potential M&A ? Contact us at: contact@genchrome.com #merger #acquisition #capitalraising #biotech #pharma

We've advised CVC Capital Partners (‘CVC’), on the completion of its previously announced carve-out acquisition of the Therakos business from global specialty pharma company Mallinckrodt. The investment in Therakos from CVC Capital Partners Fund IX will provide the resources and expertise to further develop the business and its services which improve the lives of patients. Our cross-border team was led by Global Co-Head of Private Capital Neal J Reenan and Head of US Private Capital Ian Bushner (New York), with support from Global Co-Head of Private Capital Charles Hayes (London). Head of US Leveraged Finance Allison Liff and Head of US Life Sciences Transactions Adam H. Golden provided additional leadership, alongside partners Mena Kaplan, Joseph Soltis, Emily Szasz, Lori Goodman, and Bruce McCulloch. Learn more and see the full team here: https://okt.to/KpgYOF

Sixth Street has made a $300 million strategic investment in Essential Pharma to support the UK company as it continues to provide patients around the world with critical medicines. The $300 million capital solution, consisting of growth debt and structured equity, is part of a $900 million total recapitalization. We look forward to working with Gyrus Capital and Carlyle’s AlpInvest Partners well as Essential CEO Emma Johnson and her leadership team. Read more: https://lnkd.in/gecMb6_6

Sai Life Sciences IPO opens subsequent week. GMP, worth band, date, valuation, different particulars of upcoming IPO in 10 factors - https://lnkd.in/gxsSV2pc

Citi is pleased to have acted as an advisor to CD&R on the acquisition of a 50% stake in Opella, Sanofi's Consumer Healthcare business valued at ~€16bn and has provided committed financing to the transaction. Together, CD&R and Sanofi will support Opella's growth strategy as a pure-play, global, and fast-moving consumer healthcare company. This landmark transaction is the 2nd largest Private Equity LBO in EMEA since 2007, the largest Consumer Corporate / Sponsor JV in EMEA ever and the largest M&A deal in France since 2022. Our financial sponsors franchise continues to go from strength to strength and as we look forward to 2025 expect a step-up in activity levels and our own share of the market. https://lnkd.in/eTx4YFm8